U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07537881) titled 'A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors' on April 12.
Brief Summary: The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: RC288 For Injection
Intravenous (IV) administration of RC288. Patients will continue treatment until unacceptable toxicities, dise...